CATALOGO DEI PRODOTTI DELLA RICERCA

BELLUOMINI, Lorenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.600
EU - Europa 3.484
AS - Asia 2.857
SA - Sud America 400
Continente sconosciuto - Info sul continente non disponibili 135
AF - Africa 130
OC - Oceania 19
Totale 10.625
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.457
RU - Federazione Russa 1.742
SG - Singapore 1.273
IT - Italia 604
CN - Cina 468
HK - Hong Kong 313
BR - Brasile 310
VN - Vietnam 277
DE - Germania 262
FI - Finlandia 152
GB - Regno Unito 136
FR - Francia 125
SE - Svezia 95
IN - India 94
BD - Bangladesh 91
KR - Corea 89
CA - Canada 85
IE - Irlanda 80
PL - Polonia 72
NL - Olanda 65
ID - Indonesia 42
JP - Giappone 42
ES - Italia 33
TR - Turchia 32
AR - Argentina 29
MX - Messico 28
TG - Togo 27
BJ - Benin 25
AT - Austria 21
CZ - Repubblica Ceca 20
NG - Nigeria 20
ZA - Sudafrica 17
AU - Australia 16
EC - Ecuador 15
CO - Colombia 14
PK - Pakistan 14
UA - Ucraina 14
VE - Venezuela 14
IQ - Iraq 13
JO - Giordania 11
MA - Marocco 11
MY - Malesia 11
IR - Iran 10
BE - Belgio 9
CH - Svizzera 8
PH - Filippine 8
AE - Emirati Arabi Uniti 7
EG - Egitto 7
LT - Lituania 7
SA - Arabia Saudita 7
TW - Taiwan 7
UZ - Uzbekistan 7
AZ - Azerbaigian 6
CL - Cile 6
CR - Costa Rica 6
KZ - Kazakistan 6
DK - Danimarca 5
KE - Kenya 5
PT - Portogallo 5
UY - Uruguay 5
AO - Angola 4
CY - Cipro 4
DZ - Algeria 4
HN - Honduras 4
IL - Israele 4
JM - Giamaica 4
RS - Serbia 4
TN - Tunisia 4
AM - Armenia 3
BO - Bolivia 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
NI - Nicaragua 3
PY - Paraguay 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
TT - Trinidad e Tobago 3
AL - Albania 2
BG - Bulgaria 2
DO - Repubblica Dominicana 2
GR - Grecia 2
GT - Guatemala 2
HR - Croazia 2
KH - Cambogia 2
LB - Libano 2
LV - Lettonia 2
NO - Norvegia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
OM - Oman 2
RO - Romania 2
SN - Senegal 2
SY - Repubblica araba siriana 2
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
GD - Grenada 1
HU - Ungheria 1
LK - Sri Lanka 1
LU - Lussemburgo 1
Totale 10.480
Salva come PNG Salva come JPEG
Città #
Singapore 681
Moscow 617
Ashburn 587
Dallas 548
San Jose 468
Hong Kong 299
Council Bluffs 205
Verona 170
Chandler 155
Munich 154
The Dalles 122
Los Angeles 114
Beijing 94
New York 92
Ho Chi Minh City 87
Helsinki 84
Dublin 77
Milan 68
Hanoi 56
London 49
São Paulo 44
Buffalo 41
Meda 38
Tokyo 38
Santa Clara 37
Redondo Beach 36
Chicago 32
Warsaw 32
Rome 31
Lappeenranta 28
Orem 28
Turku 28
Lomé 27
Montreal 27
Cotonou 25
Amsterdam 23
Frankfurt am Main 23
Jakarta 23
Nuremberg 23
Toronto 23
Redmond 21
Lawrence 20
Princeton 20
Atlanta 19
Boardman 19
Da Nang 19
Phoenix 19
Abuja 18
Brooklyn 18
Chennai 18
Columbus 18
Houston 18
Sindelfingen 18
Denver 17
Naples 17
Seoul 17
Haiphong 15
Mumbai 15
Stockholm 15
Washington 15
Bologna 14
Johannesburg 14
San Francisco 14
Seattle 14
Boston 13
Barnet 12
Belo Horizonte 12
New Delhi 12
Shanghai 12
Charlotte 11
Istanbul 11
Wilmington 11
Amman 10
Brno 10
Falkenstein 10
Tianjin 10
Vienna 10
Biên Hòa 9
Brussels 9
Hyderabad 9
Jacksonville 9
Paris 9
Piscataway 9
Rio de Janeiro 9
Sydney 9
Turin 9
Vicenza 9
Bursa 8
City of London 8
Guangzhou 8
Kyiv 8
Manchester 8
Ottawa 8
Poplar 8
Porto Alegre 8
Querétaro 8
Trento 8
Bengaluru 7
Chapel Hill 7
Kuala Lumpur 7
Totale 6.081
Salva come PNG Salva come JPEG
Nome #
Exploring the Complex Interplay between Myeloid-Derived Suppressor Cells (MDSCs), Interleukins, and Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC) 314
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 314
A multimodal approach to cancer-related cachexia: from theory to practice 194
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 193
A Feasibility Study Investigating an Exercise Program in Metastatic Cancer Based on the Patient-Preferred Delivery Mode 187
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 182
A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study 181
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report 180
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 170
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done 168
A qualitative study exploring the experiences and perspectives of patients with cancer attending a 12-week exercise program 167
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 165
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 165
ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR 162
A cross-sectional study exploring the perception of exercise oncology in the Italian population 160
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 159
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer 155
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 155
Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications 154
Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy? 153
Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials 146
Exploring the Association between Health-Related Physical Fitness and Quality of Life in Patients with Cancer: A Cross-Sectional Study 145
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 145
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives 143
Exercise and anemia in cancer patients: could make the difference? 142
Physical activity guidelines in oncology: a systematic review of the current recommendations 141
Impact of exercise in patients with pancreatic cancer across different treatment phases: a systematic review 141
Exercise oncology: It is time to make a change 140
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO) 136
Feasibility of a novel exercise program for patients with breast cancer offering different modalities and based on patient preference 135
Genetic and non-genetic resistance mechanisms in non-small cell lung cancer harboring (non-ALK) oncogenic fusions 135
Exploring the feasibility of a combined exercise program for patients with advanced lung or pancreatic cancer 132
Prognostic impact of Interleukin-8 levels in lung cancer: A meta-analysis and a bioinformatic validation 132
Implementation outcomes of early nutritional screening and referral for patients with thoracic cancers 132
Plasmacytoid Dendritic Cell, Slan+-Monocyte and Natural Killer Cell Counts Function as Blood Cell-Based Biomarkers for Predicting Responses to Immune Checkpoint Inhibitor Monotherapy in Non-Small Cell Lung Cancer Patients 131
Exercise and bone health in cancer: enemy or ally? 129
Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories 128
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 127
Effect of exercise across the head and neck cancer continuum: a systematic review of randomized controlled trials 125
Cross-sectional survey evaluating the psychological impact of the COVID-19 vaccination campaign in patients with cancer: The VACCINATE study 124
Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: The road to success 124
Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study 121
Combining a 9-month tailored physical exercise program with osimertinib and denosumab in a patient affected by advanced NSCLC with multiple osteolytic bone lesions: A case report 120
Nurses' perspectives on physical activity promotion in cancer patients: A qualitative research 120
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study 119
Body composition as a modulator of response to immunotherapy in lung cancer: time to deal with it 117
Exploring the role of respiratory microbiome in lung cancer: A systematic review 116
Exercise in men with prostate cancer: how to move on? 114
Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective 111
Drive the oncologists into exercise promotion in lung cancer 111
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 108
The frontier of neoadjuvant therapy in non-small cell lung cancer beyond PD-(L)1 agents 107
Exceptional Response in BRAF p.V600E-Mutant Enteric-Type Adenocarcinoma of the Lung With Cutaneous Spread: A Case Report 107
Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas 103
Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Immunotherapy Induction 103
Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance 102
HER2 Aberrations in NSCLC: So Close Yet So Far 101
Overcome the Fear of Exercise in Patients With Bone Metastases: A Qualitative Study on Patients' Perception 100
SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs 99
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer 98
The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures 97
Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy 96
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 95
Cardiac autonomic dysfunction in patients with cancer: exploring the role of physical exercise 94
Low fT3/fT4 ratio as a proxy for muscle wasting in patients with advanced non-small cell lung cancer treated with pembrolizumab 92
What is the role of physical exercise in the era of cancer prehabilitation? A systematic review 92
Willingness, preferences, barriers, and facilitators of a multimodal supportive care intervention including exercise, nutritional and psychological approach in patients with cancer: a cross-sectional study 84
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients 83
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 81
Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors 78
Effect of exercise on bone-related outcomes in patients with cancer affected by bone metastases or bone loss: a systematic review and meta-analysis 78
Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody–Drug Conjugates 76
Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk 76
Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination 74
Meta-Analysis Exploring Tyrosine Kinase Inhibitor-Induced Weight Gain in Oncogene-Addicted NSCLC 74
Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer 73
How a physical exercise program performed by patients may impact caregiver burden in cancer: a qualitative study 70
Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with "Oncogene-Addicted" Advanced Lung Adenocarcinoma: A Real-World Clinical Study 62
Physical Exercise During Neoadjuvant Treatments for Non-Small Cell Lung Cancer: The Time is Coming 62
Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke 53
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas 52
From supportive care to adjunctive treatment: the evolution in time of physical exercise and nutrition in lung cancer 51
Lung Cancer Screening: An Opportunity to Promote Physical Activity? 47
Managing lorlatinib-induced weight gain through a structured exercise intervention in an ALK+ NSCLC patient: a case report 47
PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance 45
Telehealth-delivered exercise and nutrition intervention to improve outcomes in patients with early stage non-small cell lung cancer: protocol for the multicentre STARLighT phase II (neoadjuvant) and phase III (adjuvant) trial 40
Impact of Long-Term Structured Exercise on Body Composition in an NTRK Fusion-Positive NSCLC Patient Treated With Entrectinib 38
Uncovering common transcriptional features shared by mature peripheral blood PMN-MDSCs and tumor-infiltrating neutrophils in humans 34
Structured Exercise During Chemotherapy for Locally Advanced or Metastatic Pancreatic Cancer: A Single-Arm, Feasibility Trial 28
Microbiome and EGFR-mutant non-small cell lung cancer: a complex interplay 18
Oligoprogression in NSCLC with Other Actionable Oncogenic Drivers Beyond EGFR and ALK: An Emerging Entity 14
Immunotherapy in limited-stage small cell lung cancer: riding the ADRIATIC wave toward precision 9
Real-world feasibility and effectiveness of a personalized exercise program during cancer treatment: results from the CHOiCE prospective study 8
Impact of the Oncologist's Recommendation on Exercise Levels and Quality of Life in Patients With Lung Cancer: The ORE Randomized Controlled Trial 7
Interleukin-8: a tumor-agnostic biomarker integrating cancer biology and host response across solid tumors 5
Interleukin-8 in health and disease 4
Totale 10.625
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.628
article - articoli 40.003
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 625
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.256
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022173 0 23 0 9 7 10 7 16 12 6 20 63
2022/2023463 22 50 40 93 26 111 1 25 49 12 25 9
2023/2024630 14 25 59 55 57 76 62 36 36 64 91 55
2024/20252.178 99 78 89 367 65 103 147 124 337 162 213 394
2025/20266.833 337 362 612 1.139 1.653 395 600 364 551 459 190 171
2026/2027269 114 155 0 0 0 0 0 0 0 0 0 0
Totale 10.625